CompletedPhase 2NCT00278915
Faslodex in McCune-Albright Syndrome
Studying McCune-Albright syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AstraZeneca
- Principal Investigator
- AstraZeneca Faslodex Medical Science Director, MDAstraZeneca
- Intervention
- Fulvestrant(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 1-10 years · FEMALE
- Timeline
- 2006 – 2023
Study locations (16)
- Research Site, Birmingham, Alabama, United States
- Research Site, Miami, Florida, United States
- Research Site, Lexington, Kentucky, United States
- Research Site, Baton Rouge, Louisiana, United States
- Research Site, The Bronx, New York, United States
- Research Site, Philadelphia, Pennsylvania, United States
- Research Site, Salt Lake City, Utah, United States
- Research Site, Bordeaux, France
- Research Site, Bron, France
- Research Site, Paris, France
- Research Site, Erlangen, Germany
- Research Site, Osnabrück, Germany
- Research Site, Torino, Italy
- Research Site, Moscow, Russia
- Research Site, Liverpool, United Kingdom
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00278915 on ClinicalTrials.govOther trials for McCune-Albright syndrome
Additional recruiting or active studies for the same condition.